Restrictions on obesity drug coverage force patients to pivot
Insurance coverage for popular obesity medications like Zepbound and Wegovy is being restricted or dropped, leaving patients to pay hundreds of dollars out of pocket. Millions of people have lost coverage for these drugs, sparking frustration and anger among those affected.
Patients taking popular obesity medications are facing restrictions or losing insurance coverage, forcing them to pay hundreds of dollars out of pocket. According to GoodRx research, 12 million people lost coverage for Zepbound and 12 million for Wegovy from 2025 to 2026. For those with coverage, 88% face restrictions such as prior authorization or high BMI requirements. The lack of affordable coverage is leaving many patients feeling frustrated and defeated. Some patients are being forced to switch medications or abandon treatment altogether. Insurance companies are making medical decisions for patients by limiting access to these medications.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.